A Trial of SHR-1905 in Healthy Subjects

The study will consist of one dose esclation part with a total of 5 dose levels. The Subjects will be randomized to receive SHR-1905 as reflected by the guiding principle for the dose esclation/expansion phase. Each dose group includes a screening period, a baseline period, an observational period, and a safety follow-up period.

Inclusion criteria

• Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial.
• Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form.
• Total body weight ≥45 kg at screening, and body mass index (BMI) between 18 and 28 kg/m2 (inclusive).
• For healthy subjects, no clinically significant abnormalities.
• Men and women of childbearing potential (WOCBP) must agree to take effective contraceptive methods

Exclusion criteria

• Known medical history of severe disease in cardiovascular, liver, kidney, digestive tract, mental nerve, hematology, metabolic disorders, etc.
• Severe injuries or major surgeries within 6 months before screening.
• Subjects with infecious disease.
• Hyper/Hypotension at screening and at check in.
• Clinically significant abnormalities in 12-Lead ECG
• More than 5 cigarettes daily (or products with equivalent amount of nicotine) for 3 months prior to screening
• Positive urine drug screen .
• Subject who cannot perform venous blood sampling.
• Known history or suspected of being allergic to the study drugs and their excipients.
• Use of any medicine within 4-weeks or within 5 half-lives
• History of alcohol abuse within 3 months prior to the IP administration .
• Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening
• in the investigator's judgment, may increase the risk to the subject